OAinject: Fighting osteoarthritis

In the Netherlands, more than 1.5 million people suffer from osteoarthritis – a chronic degenerative rheumatic condition of the joints that causes pain, stiffness and restriction in daily moving. As osteoarthritis is a condition that mainly occurs among older people, the number of patients is set to greatly increase due to the ageing of Dutch society. At present, there is no adequate treatment for osteoarthritis.


Maastricht University is part of the OAinject consortium, funded by the Perspectief program of the Dutch Research Council (NWO), that will develop new diagnostic tools to determine which form of osteoarthritis a patient has. This way more accurate individualised treatments can be offered in the future. The researchers will also work on innovative ways of gradually administering drugs locally over a extended period of time via an injectable drug depot in the diseased joint. With this approach, the consortium aims to develop novel methods that are expected to support a durable active lifestyle for osteoarthritis patients.

Our CAPHRI/ MUMC+ researchers Tim Welting and Pieter Emans from the Department of Orthopedic Surgery are co-initiator and member of the OAinject project. The project is led by Marcel Karperien of the University of Twente.


Programme leader: Prof. Marcel Karperien (University of Twente)
Participating knowledge institutions: Delft University of Technology, Erasmus MC, Maastricht University, Maastricht University Medical Center, Radboud university medical center, University Medical Center Utrecht, University of Twente
Companies: Chondropeptix, DSM Biomedical, IBIS Technologies, InnoCore Pharmaceuticals, 20Med Therapeutics, Nordic Bioscience, Orthros Medical, Procore, QVQ, Ssens
Other societal partners: Deventer Hospital, ReumaNederland, Dutch Society for the Replacement of Animal Testing


Also read

  • Symptoms of gluten sensitivity are partly to do with people’s expectations, if celiac disease and wheat allergy have been excluded as causes. Recent research at the universities of Maastricht and Leeds shows that the expectation that gluten causes gastrointestinal complaints plays a crucial role in...

  • Nine out of ten miscarriages happen in the first three months of pregnancy. Researchers at Maastricht University Medical Center have found that in 70% of these cases, the embryo has a genetic abnormality.

  • Marielle Wijermars and Christian Herff will receive this year's KNAW Early Career Award. The Award is intended for researchers in the Netherlands who are at the beginning of their careers and who have innovative, original ideas.